Short answer
UFP TECHNOLOGIES INC (UFPT) filed its fiscal 2025 10-K annual report with the SEC on Feb 27, 2026. It reported revenue of $603M (+19.5% year over year) and net income of $68M.
- Top risk flagged: Regulatory risk from "One Big Beautiful Bill Act" (OBBBA) enacted July 2025 with immaterial impact on income tax expense but changes to interest and depreciation rules
FY2025 key financial metrics · XBRL
- Revenue
- $603M
- +19.5% YoY
- Net income
- $68M
- +15.8% YoY
- Operating margin
- 15.3%
- −0.7 pp YoY
- Gross margin
- 28.3%
- −0.8 pp YoY
- EPS (diluted)
- $8.75
- +15.4% YoY
- ROE
- 16.1%
- −1.1 pp YoY
- Operating cash flow
- $92M
- +38.0% YoY
Source: XBRL data from the UFP TECHNOLOGIES INC (UFPT) FY2025 10-K on SEC EDGAR. USD.
UFP TECHNOLOGIES INC FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Contract development and manufacturing of custom single-use, single-patient medical devices and components
- Emphasis on diverse niche medical segments including minimally invasive surgery, infection prevention, orthopedics, and biopharma packaging
- Employee count increased notably by 700 full-time employees and 314 temporary workers YoY to 4,846 and 503 respectively
- 32 manufacturing locations with 19 ISO 13485 certified and 13 FDA registered, reinforcing regulatory compliance focus
- Sustainability effort: Newburyport MA facility uses solar providing ~6% electricity, with capacity expansion planned
Management Discussion & Analysis
- Revenue $602.8M, up 19.5% YoY from $504.4M driven by 23.2% medical market growth, acquisitions added $168.3M in 2025 vs $73.1M in 2024
- Organic sales growth 1.5% for 2025; largest customers Intuitive Surgical SARL 24.3% and Stryker Corporation 21.5% of sales in 2025
- Incremental labor costs from AJR labor issue $6.3M impacting cost-of-sales and operational efficiencies in 2025
- Tariffs had immaterial impact on 2025 results despite dynamic trade environment and increased US tariffs on foreign imports
- Cyber incident detected February 2026, no material impact on operations or financial condition as of filing date, ongoing investigation
Risk Factors
- Regulatory risk from "One Big Beautiful Bill Act" (OBBBA) enacted July 2025 with immaterial impact on income tax expense but changes to interest and depreciation rules
- Macroeconomic risk from inflation and bank failures could affect long-term capital access and liquidity despite $91.9M cash from operations in 2025
- Operational risk from AJR Labor Issue reduced gross margin by 1.0% in 2025, impacting cost control and profitability
- Competitive risk from increased acquisitions in 2024-2025 contributed $168.3M sales but increased SG&A by $17.8M, pressuring expense efficiency
- Financial risk from $135.5M debt outstanding at 5.1% interest with covenants under third amended credit agreement maturing in 2029
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.